Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease (STAAR)
A Phase I/II, Multicenter, Open-Label, Single-Dose, Dose-Ranging Study to Assess the Safety and Tolerability of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy, in Subjects With Fabry Disease (STAAR)
Sponsor: Sangamo Therapeutics
A observational or N/A phase clinical study on Fabry Disease, this trial is completed. The trial is conducted by Sangamo Therapeutics and has accumulated 23 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
23 versions recorded-
Apr 16, 2026 — Present [daily]
Completed
Phase: PHASE1/PHASE2 → None
-
Jun 2025 — Apr 2026 [monthly]
Completed PHASE1/PHASE2
Status: Active Not Recruiting → Completed
-
Sep 2024 — Jun 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
▶ Show 18 earlier versions
-
Jan 2024 — Jun 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Aug 2023 — Jan 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Jul 2023 — Aug 2023 [monthly]
Recruiting PHASE1_PHASE2
-
May 2023 — Jul 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Mar 2023 — May 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Dec 2022 — Mar 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2022 — Dec 2022 [monthly]
Recruiting PHASE1_PHASE2
-
May 2022 — Sep 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Apr 2022 — May 2022 [monthly]
Recruiting PHASE1_PHASE2
-
May 2021 — Apr 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Apr 2021 — May 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2021 — Apr 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
-
May 2020 — Dec 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Mar 2020 — May 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2020 — Mar 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Nov 2019 — Jan 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2019 — Nov 2019 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Jul 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
This is the first in human treatment with ST-920, an adeno-associated virus (AAV2/6) vector encoding the complementary deoxyribonucleic acid (cDNA) for human a-Gal A. The purpose of this study is to evaluate the safety and tolerability of ascending doses of ST-920. ST-920 aims to provide stable, long-term production of α-Gal A at therapeutic levels in subjects with Fabry disease. The constant production of α-Gal A in humans should, importantly, enable reduction and potentially clearance of Fabry disease substrates Gb3 and lyso-Gb3. On Day 1, patients will be infused intravenously with a single dose of ST-920 and followed for a period of 52 weeks.
Contact Information
- Sangamo Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .